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Ethics in clinical researchq
Silvio Garattini*, Vittorio Bertele’
Mario Negri Institute for Pharmacological Research, Via G. La Masa 19, 20156 Milan, ItalyR&D of new drugs is driven by pharmaceutical companies that invest considerable amounts of money for this purpose.
This may introduce bias, to emphasize the clinical value of drugs to be allowed onto the market. Bias is caused by meth-
odological ﬂaws including the population under study, the choice of inadequate comparators or of their dosage, the adop-
tion of surrogate or composite endpoints, the decision to publish mainly positive ﬁndings or to overlook some safety
concerns, etc. All this happens in a legal context that requires no added value for new drugs to be approved for the market.
This encourages the use of placebo even when active comparators are available, or the search for non-inferiority of new
products in comparison with active comparators. Superiority over placebo and non-inferiority to active comparators
may allow drugs onto the market that are in fact less active (or safe, tolerable, convenient, etc.) than those already avail-
able, usually with consolidated properties and lower costs. In addition, they do not meet patients’ or physicians’ needs of
deﬁning the place in therapy and respective roles of new and available treatments. The current legislative and regulatory
setting seems designed to meet commercial interests rather than public health needs.
 2009 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
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Planning, conducting and concluding clinical trials
has always been a matter for ethical discussion because
patients may risk receiving treatments that are not
always potentially in their interest. A vast amount of lit-
erature deals with the principles for recruiting patients
for clinical studies, who are free to participate and can
withdraw at any time. Trials with patients such as pris-
oners who were obliged to participate, or studies done in0168-8278/$36.00  2009 European Association for the Study of the Liver.
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selective serotonin reuptake inhibitors.developing countries without adequate external control
have been condemned. Although there is always a need
for active vigilance the ethics of clinical trials today is
essentially conﬁned to the preparation and conduct of
the protocol because the results can be considerably
inﬂuenced by apparently minor details. These details
require attention considering that most clinical trials
are supported, executed and analyzed by pharmaceutical
companies which have an obvious conﬂict of interest in
testing new drugs whose development has incurred con-
siderable expenditure. Clinical trials that require thou-
sands of patients have a high cost, sometimes running
to hundreds of millions of euros. Possibly unintention-
ally, this may introduce bias that aﬀects the outcome
of the study. There is also a substantial gap between
the capacity of industry to utilize experts in clinical trial
methodology and the speciﬁc knowledge of the members
of the ethical committees responsible in many countries
for approval of the protocols. This article underlines
some of the biases in the scientiﬁc literature concerning
phase 3 randomized controlled trials (RCT).Published by Elsevier B.V. All rights reserved.
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the pharmaceutical industry for several reasons. The
European Medicines Agency (EMEA), which approves
new drugs and follows them on the market for all the
Member States of the European Union (EU) depends –
unlikemost single countries – on theDirectorate of Indus-
try and Enterprise, suggesting that drugs are considered
more as consumer goods than tools to cure diseases. Per-
haps it is in relation to this link that the EU legislation
establishes that new drugs must be required only to prove
quality, eﬃcacy and safety, as if they were in a therapeutic
vacuum. It is therefore not required tomake comparisons
with drugs already available for the same indication [1]. In
other words new drugs may well be less useful than the
ones already on the market because the legislation does
not ask for any ‘‘added value”. Finally, the entire dossier
for the approval of new drugs or for the extension of indi-
cations is assembled by the industry, which has a direct
interest in predominantly stressing favourable eﬀects.
The public or its representatives have no chance to consult
the dossier because the entire procedure is secret, thus
penalizing the rights of the patients who havemade them-
selves available – even with some risk – for clinical trials.
This and other aspects of the EU legislation are responsi-
ble for several biases that have come to light in phase 3
RCT.2. The excessive use of placebo
The Helsinki declaration states that placebo should
be used only when there are no eﬀective drugs for a
given indication. However, this ethical requirement is
not followed in many conditions. For instance in trials
with an add-on design one of the two arms receives
the new drug and the other a placebo, while both are
given an eﬀective drug that is already available which,
as such, cannot be omitted; this is acceptable if there
is no previous study showing that another drug has
already shown a beneﬁcial eﬀect for the same indication
with the same design. The RCTs of new anti-TNFa or
other so-called disease modifying anti-rheumatic drugs
(DMARD) is paradigmatic: they are added to metho-
trexate in comparison with placebo even though other
drugs are already known to act synergistically with
methotrexate [2]. Another example is in diabetes. Exena-
tide has been found to be more active than placebo in
patients treated with a glitazone and metformin in low-
ering fasting plasma glucose and glycosylated hemoglo-
bin (Hb A1c) [3]. This design has exposed diabetic
patients treated with placebo to useless risk. A fair com-
parison would have been to use one of the many antidi-
abetic agents available on the market instead of placebo.
It is warrying that the FDA has recently refused to
accept the Helsinki declaration, stating that placebo is
necessary for scientiﬁc reasons even if comparators areavailable [4], arousing protest from clinical investigators
[5]. Practically, the EMEA is on the same line even if
there are no oﬃcial statements. This attitude, which is
ethically unacceptable, is essentially dictated by the refu-
sal to consider added value as mandatory for all new
drugs. In fact only if the design of a RCT is based on
superiority is there no need for a placebo arm.3. Design of clinical trials
There is an increasing tendency to utilize non-inferi-
ority designs for RCT. In a recent analysis of anticancer
agents approved by the EMEA, out of 21 approvals for
a new indication only nine cases had a phase 3 RCT but
in six cases the design was of non-inferiority [6]. This
design cannot establish the drug’s real role in the thera-
peutic armamentarium [7] and therefore it is ethically
questionable to exploit patients when the sole purpose
is to obtain a slice of the market [8]. Those supporting
non-inferiority trials argue that patients do not always
respond to the same drug and therefore it is useful to
have other drugs even if they are less active. However,
the answer to this is to select patients unresponsive to
a given drug and then to carry out a superiority trial
with the new drug versus placebo.
Others consider that a drug may have a better toxico-
logical proﬁle while being non-inferior in terms of eﬃ-
cacy. This could be clariﬁed better by a superiority
trial addressing safety, although the real toxic proﬁle
of a drug only becomes evident once it is on the market.
Others consider that non-inferiority trials may be justi-
ﬁed when a drug could lead to better compliance. How-
ever, better compliance has less meaning if does not
result in a better outcome, to be tested by a superiority
trial. A discussion of the ethical aspects of non-inferior-
ity trials is available [9].
In addition, what is presented as equivalent is fre-
quently an excuse not to look for a diﬀerence [10,11].
Moher et al. [12] reported that in 64 percent of 383 RCTs
a diﬀerence in eﬃcacy could be detected only if it was
more than 50 percent more or less than the comparator
and in 84 percent of cases only if the gap was more than
25 percent.
Fortunately, there have been some reactions from the
regulatory agencies in respect to non-inferiority trials
recently. The FDA declared that antibiotics studied with
non-inferiority designs will not be accepted for approval
[13]. EMEA in its guidelines advises that non-inferiority
trials will not be accepted anymore for anti-Parkinson
and anti-Alzheimer indications [14,15].4. Inclusion and exclusion criteria
The inclusion criteria for most RCT give priority to
young males. Women, children and the elderly are
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lems in terms of their sensitivity to adverse reactions
[16]. However, older patients in particular are the ones
receiving the majority of drug prescriptions. Rochon
et al. [17] found that out of 9664 patients in RCT dealing
with osteoarthritis and rheumatoid arthritis only 2.1
percent were over 65 years and only 14 patients were
older than 75 years. In a Health Technologic Assess-
ment report [18] concerning the use of bevacizumab
and cetuximab in metastatic colorectal cancer, patients
included were 5–10 years younger than the UK popula-
tion bearing this disease, raising doubts about the gener-
alizability of the results. Similar considerations hold for
children, who are usually treated with doses adjusted
according to the body weight established in trials in
adults, ignoring the fact that a growing body has reac-
tions that are likely to be diﬀerent from adults. It is
worrying to consider that about 50 percent of drugs
currently prescribed to children or adolescents have
never been studied in a RCT [19].5. Inadequate comparators
When new drugs are compared with drugs already
available for the same indication the ethical requirement
is that the selected comparator must be the best avail-
able and must be utilized at an optimal dosage and sche-
dule. This is not always the case. A well known example
of the choice of comparator was the new cyclooxygen-
ase-2 speciﬁc inhibitors, studied as anti-inﬂammatory
agents. The selection of diclofenac as a comparator
masked the cardiotoxicity of rofecoxib while the choice
of naproxen would have revealed this important adverse
reaction [20].
Mycophenolate, presented as a considerable improve-
ment for the treatment of organ rejection [21], was
recently found to be comparable to the older drug aza-
thioprine in terms of eﬃcacy and safety, though not
price [22]. For the same indications tacrolimus was
found more active than ciclosporin [23] but, on measur-
ing the trough concentration of ciclosporin, Schieppati
et al. [24] found that the doses utilized were not able
to reach what is considered the optimal concentration.
The new atypical or second-generation antipsychotic
agents are usually considered to show an advantage over
haloperidol in terms of extrapyramidal eﬀects, but
Geddes et al. [25] found this happened only when the
dose of haloperidol exceeded 12 mg a day. The claimed
superiority of atypical or second-generation antipsy-
chotic drugs over the older drugs of this class is no
longer true in the light of a meta-analysis of 150
randomized trials [26].
This analysis found that as a group the second-gener-
ation antipsychotics were no more eﬀective, did not
improve speciﬁc symptoms, and had no clearly diﬀerentside-eﬀect proﬁles from the ﬁrst-generation drugs, and
were also less cost-eﬀective. Therefore, the ‘‘atypical”
antipsychotics are now regarded as an ‘‘invention only”,
manipulated by the drug industry for marketing pur-
poses [27].
These examples illustrate vividly how the choice of
comparator and its dosage can considerably inﬂuence
the outcome of a test drug in terms of toxicity or
eﬃcacy.6. Surrogate end-points
Quality of life, morbidity and mortality should
always be the primary hard end-points for evaluating
new drugs because these outcomes reﬂect signiﬁcant
therapeutic beneﬁts. However, in some cases an end-
point that closely correlates with a hard end-point can
be used as a surrogate although the therapeutic eﬃcacy
must always be proved.
Because of the long duration and the consequent cost
of a therapeutic RCT there is a tendency to abuse surro-
gate end-points, which may be misleading. For instance
encainide and ﬂecainide decrease arrhythmias but
increase mortality [28]. Estrogens were supposed to be
cardioprotective in menopausal women because they
increased the surrogate end-point high-density lipopro-
tein (HDL) cholesterol [29]. However, large RCT have
not been able to demonstrate any prevention of cardio-
vascular events [30]. Torcetrapib was also quite active in
raising HDL-cholesterol but unfortunately the drug
increased mortality [31]. Sulfonylureas lower glycosyl-
ated hemoglobin but increase the risk of myocardial
infarction [32].
In these cases an eﬀect on a surrogate end-point does
not result in a therapeutic advantage. Similarly, an eﬀect
of anticancer agents on tumour size is not always predic-
tive of an increase in overall survival, because of the pos-
sibility of adverse reactions. This is because a drug does
not have merely a single beneﬁcial eﬀect but a number of
side eﬀects too which may counteract the beneﬁts.
Finally, the use of surrogate end-points as an out-
come for drug approval is unethical when there are
already drugs on the market for the same indication
which have already proven their clinical eﬃcacy. A case
in point is the approval of atorvastatin and rosuvastatin
on the basis of cholesterol-lowering activity when simva-
statin and pravastatin were already known to have ben-
eﬁcial eﬀects on cardiovascular events and mortality.7. Composite end-points
Since the eﬃcacy of some drugs has already reached a
high level, proving that a new drug is superior would
require too large a population and too many years so
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posite end-points [33], meaning adding in diﬀerent
events as outcome measures. For example, in the cardio-
vascular area it is possible to add myocardial infarction
and revascularization procedures to mortality. How-
ever, it would be misleading to claim this composite
end-point if revascularization procedures were more
common outcomes than death or infarction or – even
more – if the new drugs had a large eﬀect on revascular-
ization but not on death or infarction.
A typical example is a trial on clopidogrel where the
composite end-point was signiﬁcant only for coronary
artery occlusion, but not for recurrent ischemia or death
[34]. Ferreira-Gonzales et al. [35] analyzed a number of
cardiovascular studies where composite end-points rep-
resented the outcome. By stratifying the component of
the composite end-points on the basis of their impor-
tance for patients it was found that the contributions
of minor or moderate categories were driving the signif-
icance of the composite end-points.
The DREAM trial of rosiglitazone in the prevention
of diabetes in patients with impaired fasting glucose or
glucose tolerance (or both), adopted the composite pri-
mary outcome of diabetes or death [36]. The primary
outcome was statistically highly signiﬁcant, although
there was no diﬀerence in deaths in the groups (1.1 per-
cent in the rosiglitazone group and 1.3 percent in the
placebo group). Following standard practice, the FDA
would react to an application for extension of the mar-
keting authorization by granting authorization for the
composite outcome but this would wrongly endorse
the idea that mortality was reduced.8. Selective publication
The perception of drug eﬃcacy is misled by publica-
tion selectivity because positive trials have about three
times more chance of being published than negative ones
[37]. Melander et al. [38] found that out of 42 studies
evaluating antidepressant agents acting on serotonin
(SSRI) only 25 were published and of these 19 reported
positive results and only six negative ones. It is clearly
diﬃcult to obtain objective information if negative data
are not reported.
Melander’s ﬁndings were indirectly conﬁrmed by a
recent analysis by Kirsch et al. [39]. These authors had
access to all the studies deposited at the FDA, published
and unpublished, showing that SSRI are active only on
severe depression and not in mild depressive conditions,
though this is not evident from the scientiﬁc literature.
Selective reporting of RCT may bias meta-analyses,
creating a favourable impression of drug eﬃcacy, and
may misdirect guidelines based on published results.
There is also selective reporting on the outcome of clinical
trials [40] as shown by an analysis of 122 journal articlesconcerning 3736 outcomes; 50 percent of eﬃcacy and 65
percent of harmful outcomes were reported incompletely.9. Selective reporting of adverse reactions
Atypical antipsychotics were presented as an
improvement over phenothiazines and butyrophenones
because they were less likely to induce extrapyramidal
eﬀects. This was the basis for the rapid increase in their
prescriptions. However, subsequent independent investi-
gations provided evidence that atypical antipsychotics
cause weight gain and can raise blood cholesterol and
glucose and glycosylated hemoglobin – all important
risk factors for cardiovascular diseases and diabetes [41].
In another ﬁeld coxibs were considered better anti-
inﬂammatory agents because of their lower gastrotoxic-
ity [42]. It took several years for it to become clear that
coxibs caused increases in myocardial infarction and
heart failure [43]. Even the reduced gastrotoxicity could
not be conﬁrmed. Ironically, because of physicians’ con-
ﬁdence in coxibs, English hospitals saw an increase in
cases with gastrointestinal bleeding. Eventually these
drugs were withdrawn by the industry, not by the
FDA or EMEA.10. Conﬂict of interest
There is no need to stress this point because conﬂict
of interest is a source of other biases. It is sometimes
worrying to see that most papers include long lists of
disclosure of possible conﬂicts of interest, sometimes
longer than the abstract. Kjaergard and Als-Nielsen
[44] pointed out that RCT signiﬁcantly favoured exper-
imental interventions if ﬁnancial competing interests
were declared; other competing interests were not signif-
icantly associated with their conclusions. Cho and Bero
[45] and Baker et al. [46] reached similar conclusions.
Wilcock et al. [47] found that galantamine was better
than donepezil in alleviating symptoms of Alzheimer
disease, while Jones et al. [48] found the opposite. The
superiority of one drug or the other corresponded to
the producer that supported the study. However, an
independent RCT (AD2000) questioned the activity of
donepezil in Alzheimer disease [49].
The independent ALLHAT study on antihyperten-
sive agents showed that a-adrenergic inhibitors had a
less favourable beneﬁt-risk ratio than other anti-hyper-
tensive drugs, and the old diuretics proved better than
more recent drugs [50].11. Concluding remarks
RCTs are still the best way to assess the eﬃcacy and
safety of new drugs in order to ﬁnd their place in
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tical products and the dominance of marketing in ‘‘big
pharma” tend to introduce biases in planning, conduct-
ing and evaluating new drugs, with the complicity of the
European legislation. It is therefore important to change
the location of EMEA which should be under the
umbrella of the General Direction of Health and Con-
sumers, to abolish the conﬁdentiality of pharmacologi-
cal and clinical data and to introduce the concept of
added value in approving the marketing of new drugs.
More independent research is needed, supported by
public resources, to challenge results of industry pro-
moted trials. Drug approval should not rely solely on
data produced by the pharmaceutical industry. A recent
BMJ editorial suggested that at least one pivotal phase 3
study should be carried out by clinicians independent of
pharmaceutical companies [51].
Measures are needed to encourage physicians to look
critically at papers with long lists of possible conﬂict of
interest, and to pick up signs of bias in RCT. Similarly,
ethics committees should be more critical in evaluating
protocols, not approving those designed purely to sup-
port commercial interests rather than the needs of
patients. Scientiﬁc societies should also pay more care
when issuing guidelines to the problem of selective pub-
lication. RCTs should be required to ask important clin-
ical questions which cannot be answered by surrogate
end-points or non-inferiority designs. With a more crit-
ical approach industry would be obliged to produce new
drugs with added value while National Health Services
with a better understanding of biases will be able to
gauge the value of drugs better and will have a broader
base for deciding on their reimbursability.
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